Intellikine secures funds for pipeline push
This article was originally published in Scrip
Executive Summary
Intellikine is to ramp up its clinical pipeline after investors committed up to $51 million into the company. The US firm will use the cash to push its phosphatidyinositol-3-kinase (PI3K) pathway inhibitors towards Phase I studies.